Special offer until 30th of June 2017!

April 4, 2017

Special offer for mAb BC-1 or C-6 and mAb IST-6 prolonged to 30th of June 2017 :  0.5 mg of mAb BC-1 or C-6 and 0.5 mg of mAb IST-6 for 750 Euro until 30th of June 2017!

ANGIOGENESIS

February 7, 2017

Special offer: 0.5 mg of mAb BC-1 or C-6 and 0.5 mf of mAb IST-6 for 750 Euro until 30th of April 2017! The extra domain B (EDB) of fibronectin (FN) is a marker of angiogenesis. The mAbs  BC-1 and IST-6  react with FN containing and not containing EDB respectively. Using this pair of mAbs […]

FREE DELIVERY

February 7, 2017

Special offer: free delivery for orders over 500 euro within Europe until 30th of April 2017!

NEW FIBRONECTIN PREPARATIONS: 100% EDA + and 100% EDB+

September 13, 2016

For more informations: s-p004 s-p005

SPECIAL OFFER FOR OC-20: 2 mg per 1000 EURO!

September 1, 2016

C6: A NEW PUBLICATION

August 26, 2016

C6: Monoclonal antibody specific for a fibronectin epitope situated at the interface between the oncofoetal extra-domain B and the repeat III8.        

SPECIAL OFFER FROM SIRIUS oct2015

October 16, 2015

SPECIAL OFFER FROM SIRIUS-BIOTECH Valid until: December 31th, 2015 Antibodies to B-Fibronectin, a marker of angiogenesis. B-FN is accumulated around neovasculature during angiogenic processes  and thereby provides one of the best marker for angiogenesis and it is a component of the ECM of the niche of stem cells. Monoclonal antibodies BC-1 and C6: 1mg 600 […]

Special offer of monoclonal antibody OC-20 or IST-9: 2 mg for 600 Euro!!

May 26, 2015

Special offer for the novel mAb OC-20 to human and mouse periostin or for the anti-ED-A fibronectin mAb IST-9 : 2 mg 600 Euro!!! OC-20 The epitope recognized by the mAb OC-20 reacts with a novel cell binding site on the periostin molecule. In vivo OC-20 is able to inhibit tumor growth (Orecchia et al. Identification of a novel […]

Thermolysin human plasma fibronectin fragments

October 22, 2012

Sirius-biotech offers the following thermolysin fragments of human fibronectin.

SIRIUS-BIOTECH ACQUIRED A NOVEL ANTI HUMAN PERIOSTIN MONOCLONAL ANTIBODY WITH INHIBITORY ACTIVITY ON TUMOR GROWTH AND ANGIOGENESIS

April 5, 2012

Sirius-biotech has acquired from the National Cancer Institute of Genoa a novel anti-periostin antibody, OC-20, that shows inhibitory effects on tumor growth and angiogenesis in vivo in tumor-bearing mice. OC-20 reacts with an epitope localised in the second FAS1 domain (FAS1-2) of periostin. This epitope is a new cell binding site of perostin, interacting with the […]